Philippa Musoke1, Alexander J Szubert2, Victor Musiime3, Kusum Nathoo4, Patricia Nahirya-Ntege5, Kuda Mutasa6, David Eram Williams7, Andrew J Prendergast8, Moira Spyer2, A Sarah Walker2, Diana M Gibb2. 1. Baylor-Uganda, Paediatric Infectious Diseases Clinic, Mulago Hospital, Kampala, Uganda; Makerere University College of Health Sciences, Kampala, Uganda. 2. MRC Clinical Trials Unit at University College London, London, UK. 3. Joint Clinical Research Centre, Kampala, Uganda; Makerere University College of Health Sciences, Kampala, Uganda. 4. University of Zimbabwe College of Health Sciences, Harare, Zimbabwe. 5. Medical Research Council/Uganda Virus Research Institute Uganda Research Unit on AIDS, Entebbe, Uganda. 6. Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe. 7. Joint Clinical Research Centre, Kampala, Uganda. 8. Queen Mary University of London, London, UK.
Abstract
OBJECTIVES: To assess the impact of exposure to single-dose nevirapine (sdNVP) on virological response in young Ugandan/Zimbabwean children (<3 years) initiating antiretroviral therapy (ART), and to investigate other predictors of response. DESIGN: Observational analysis within the ARROW randomized trial. METHODS: sdNVP exposure was ascertained by the caregiver's self-report when the child initiated non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART. Viral load was assayed retrospectively over a median 4.1 years of follow-up. Multivariable logistic regression models were used to identify independent predictors of viral load below 80 copies/ml, 48 and 144 weeks after ART initiation (backwards elimination, exit P = 0.1). RESULTS: Median (IQR) age at ART initiation was 17 (10-23) months in 78 sdNVP-exposed children vs. 21 (14-27) months in 289 non-exposed children (36 vs. 20% <12 months). At week 48, 49 of 73 (67%) sdNVP-exposed and 154 of 272 (57%) non-exposed children had viral load below 80 copies/ml [adjusted odds ratio (aOR) 2.34 (1.26-4.34), P = 0.007]; 79 and 77% had viral load below 400 copies/ml. Suppression was significantly lower in males (P = 0.009), those with higher pre-ART viral load (P = 0.001), taking syrups (P = 0.05) and with lower self-reported adherence (P = 0.04). At week 144, 55 of 73 (75%) exposed and 188 of 272 (69%) non-exposed children had less than 80 copies/ml [aOR 1.75 (0.93-3.29), P = 0.08]. There was no difference between children with and without previous sdNVP exposure in intermediate/high-level resistance to NRTIs (P > 0.3) or NNRTIs (P > 0.1) (n = 88) at week 144. CONCLUSION: Given the limited global availability of lopinavir/ritonavir, its significant formulation challenges in young children, and the significant paediatric treatment gap, tablet fixed-dose-combination NVP-based ART remains a good alternative to syrup lopinavir-based ART for children, particularly those over 1 year and even if exposed to sdNVP.
OBJECTIVES: To assess the impact of exposure to single-dose nevirapine (sdNVP) on virological response in young Ugandan/Zimbabwean children (<3 years) initiating antiretroviral therapy (ART), and to investigate other predictors of response. DESIGN: Observational analysis within the ARROW randomized trial. METHODS: sdNVP exposure was ascertained by the caregiver's self-report when the child initiated non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART. Viral load was assayed retrospectively over a median 4.1 years of follow-up. Multivariable logistic regression models were used to identify independent predictors of viral load below 80 copies/ml, 48 and 144 weeks after ART initiation (backwards elimination, exit P = 0.1). RESULTS: Median (IQR) age at ART initiation was 17 (10-23) months in 78 sdNVP-exposed children vs. 21 (14-27) months in 289 non-exposed children (36 vs. 20% <12 months). At week 48, 49 of 73 (67%) sdNVP-exposed and 154 of 272 (57%) non-exposed children had viral load below 80 copies/ml [adjusted odds ratio (aOR) 2.34 (1.26-4.34), P = 0.007]; 79 and 77% had viral load below 400 copies/ml. Suppression was significantly lower in males (P = 0.009), those with higher pre-ART viral load (P = 0.001), taking syrups (P = 0.05) and with lower self-reported adherence (P = 0.04). At week 144, 55 of 73 (75%) exposed and 188 of 272 (69%) non-exposed children had less than 80 copies/ml [aOR 1.75 (0.93-3.29), P = 0.08]. There was no difference between children with and without previous sdNVP exposure in intermediate/high-level resistance to NRTIs (P > 0.3) or NNRTIs (P > 0.1) (n = 88) at week 144. CONCLUSION: Given the limited global availability of lopinavir/ritonavir, its significant formulation challenges in young children, and the significant paediatric treatment gap, tablet fixed-dose-combination NVP-based ART remains a good alternative to syrup lopinavir-based ART for children, particularly those over 1 year and even if exposed to sdNVP.
Authors: Victoria A Johnson; Vincent Calvez; Huldrych F Gunthard; Roger Paredes; Deenan Pillay; Robert W Shafer; Annemarie M Wensing; Douglas D Richman Journal: Top Antivir Med Date: 2013 Feb-Mar
Authors: Shahin Lockman; Roger L Shapiro; Laura M Smeaton; Carolyn Wester; Ibou Thior; Lisa Stevens; Fatima Chand; Joseph Makhema; Claire Moffat; Aida Asmelash; Patrick Ndase; Peter Arimi; Erik van Widenfelt; Loeto Mazhani; Vladimir Novitsky; Stephen Lagakos; Max Essex Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Quirine Fillekes; Veronica Mulenga; Desiré Kabamba; Chipepo Kankasa; Margaret J Thomason; Adrian Cook; Chifumbe Chintu; Diana M Gibb; A Sarah Walker; David M Burger Journal: AIDS Date: 2013-08-24 Impact factor: 4.177
Authors: Elise Arrivé; Marie-Louise Newell; Didier K Ekouevi; Marie-Laure Chaix; Rodolphe Thiebaut; Bernard Masquelier; Valériane Leroy; Philippe Van de Perre; Christine Rouzioux; François Dabis Journal: Int J Epidemiol Date: 2007-05-28 Impact factor: 7.196
Authors: Jane C Lindsey; Michael D Hughes; Avy Violari; Susan H Eshleman; Elaine J Abrams; Mutsa Bwakura-Dangarembizi; Linda Barlow-Mosha; Portia Kamthunzi; Pauline M Sambo; Mark F Cotton; Harry Moultrie; Sandhya Khadse; Werner Schimana; Raziya Bobat; Bonnie Zimmer; Elizabeth Petzold; Lynne M Mofenson; Patrick Jean-Philippe; Paul Palumbo Journal: Pediatr Infect Dis J Date: 2014-08 Impact factor: 2.129
Authors: Quirine Fillekes; Veronica Mulenga; Desiré Kabamba; Chipepo Kankasa; Margaret J Thomason; Adrian Cook; Alex Ferrier; Chifumbe Chintu; A Sarah Walker; Diana M Gibb; David M Burger Journal: AIDS Date: 2012-09-10 Impact factor: 4.177
Authors: Adeodata Kekitiinwa; Alexander J Szubert; Moira Spyer; Richard Katuramu; Victor Musiime; Tawanda Mhute; Sabrina Bakeera-Kitaka; Oscar Senfuma; Ann Sarah Walker; Diana M Gibb Journal: Pediatr Infect Dis J Date: 2017-06 Impact factor: 2.129
Authors: Andrzej Bienczak; Paolo Denti; Adrian Cook; Lubbe Wiesner; Veronica Mulenga; Cissy Kityo; Addy Kekitiinwa; Diana M Gibb; David Burger; Ann S Walker; Helen McIlleron Journal: AIDS Date: 2017-04-24 Impact factor: 4.177
Authors: Veronica Mulenga; Victor Musiime; Adeodata Kekitiinwa; Adrian D Cook; George Abongomera; Julia Kenny; Chisala Chabala; Grace Mirembe; Alice Asiimwe; Ellen Owen-Powell; David Burger; Helen McIlleron; Nigel Klein; Chifumbe Chintu; Margaret J Thomason; Cissy Kityo; A Sarah Walker; Diana M Gibb Journal: Lancet Infect Dis Date: 2015-10-05 Impact factor: 25.071
Authors: Ashley Bjorklund; Tina Slusher; Louise Tina Day; Mariya Mukhtar Yola; Clark Sleeth; Andrew Kiragu; Arianna Shirk; Kristina Krohn; Robert Opoka Journal: Front Pediatr Date: 2022-01-31 Impact factor: 3.418
Authors: Victor Musiime; Philip Kasirye; Bethany Naidoo-James; Patricia Nahirya-Ntege; Tawanda Mhute; Adrian Cook; Lincoln Mugarura; Marshall Munjoma; Navdeep K Thoofer; Emmanuel Ndashimye; Immaculate Nankya; Moira J Spyer; Margaret J Thomason; Wendy Snowden; Diana M Gibb; Ann Sarah Walker Journal: AIDS Date: 2016-07-17 Impact factor: 4.177